
Personalized Cancer Vaccine Cuts Melanoma Death Risk by Half
The story in brief
Merck and Moderna’s intismeran, used with Keytruda, cuts melanoma death risk by half. It targets neoantigens—proteins unique to cancer cells—enabling immune recognition. The first therapy of its kind, it shows meaningful benefits. While Keytruda works for several cancers, many Indian patients can’t afford it, even with aid. mRNA carries genetic instructions, but Keytruda remains unaffordable for many.